The American Journal of Medicine
Volume 121, Issue 8, Supplement 1 , Pages S8-S15 , August 2008

Management of Hypertension in Patients with Cardiac Disease: Use of Renin-Angiotensin Blocking Agents

  • L. Michael Prisant, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to L. Michael Prisant, MD, Divisions of Hypertension and Clinical Pharmacology, Medical College of Georgia, HB-2010, 1467 Harper Street, Augusta, Georgia 30912.

References 

  1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828
  2. Pfeffer MA, Braunwald E, Moye LA, et al. SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med. 1992;327:669–677
  3. Køber L, Torp-Pedersen C, Carlsen JE, et al. Trandolapril Cardiac Evaluation (TRACE) Study Group A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676
  4. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. [published correction appears in N Engl J Med. 2004;350:203] N Engl J Med. 2003;349:1893–1906
  5. Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  6. Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Unger T. Vascular remodeling in systemic hypertension. Am J Cardiol. 1993;71:2E–7E
  7. Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens. 1991;4(pt 1):51–55
  8. McVeigh GE. Effects of perindopril on cardiovascular remodeling. Am J Cardiol. 2001;88(suppl 7A):28i–35i
  9. Tamura T, Said S, Harris J, et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation. 2000;102:253–259
  10. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173–1178
  11. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. Circulation. 1994;90:1731–1738
  12. Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  13. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28–E32
  14. Fox KM EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  15. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  17. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288:3039–3042
  18. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med. 2003;139:777–780
  19. Davis BR, Furberg CD, Wright JT, et al. ALLHAT: setting the record straight. Ann Intern Med. 2004;141:39–46
  20. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST), a randomized controlled trial. JAMA. 2003;290:2805–2816
  21. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–1574
  22. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781
  23. Cleland JG, Tendera M, Adamus J, et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345
  24. Carson P, Massie BM, McKelvie R, et al. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005;11:576–585
  25. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–352
  26. Mensah GA, Pappas TW, Koren MJ, et al. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993;11:1429–1440
  27. Mathew J, Sleight P, Lonn E, et al. Heart Outcomes Prevention Evaluation (HOPE) Investigators Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615–1621
  28. Ruzicka M, Yuan B, Harmsen E, Leenen FH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993;87:921–930
  29. Onodera T, Okazaki F, Miyazaki H, et al. Perindopril reverses myocyte remodeling in the hypertensive heart. Hypertens Res. 2002;25:85–90
  30. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  31. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–1462
  32. Kenchaiah S, Davis BR, Braunwald E, et al. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: insights from the Survival and Ventricular Enlargement trial. Am Heart J. 2004;148:356–364
  33. Kenchaiah S, Pfeffer MA, St. John Sutton M, et al. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). Am J Cardiol. 2004;94:1–8
  34. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42:1446–1453

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00503-2

doi: 10.1016/j.amjmed.2008.05.017

The American Journal of Medicine
Volume 121, Issue 8, Supplement 1 , Pages S8-S15 , August 2008

Article Tools

* Image Usage & Resolution